Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Directorate Change

17 Aug 2016 07:00

RNS Number : 3418H
Consort Medical PLC
17 August 2016
 

Consort Medical plc

17 August 2016

 

 

Directorate Change

 

Consort Medical plc (LSE: CSRT) ("Consort", "Consort Medical" or the "Group"), a leading, global, single source pharma services drug and delivery device company, today announces that Richard Cotton, Group Chief Financial Officer, will be leaving the business in order to accept the position of Chief Financial Officer at Dechra Pharmaceuticals PLC, a FTSE 250 Company. Richard will leave Consort after the interim results in December 2016, to ensure an orderly transition. The search for his successor is underway, and a further announcement will be made in due course.

 

Dr Peter Fellner, Chairman of Consort Medical, commented:

 

"Richard has made many significant contributions during his four years at Consort. Not least of these has been his central role in the acquisition and integration of Aesica, allowing Consort to begin to realise its vision of becoming a leading single source pharma services drug and delivery device company. Richard leaves the Company in robust financial shape and well positioned to support the growth aspirations of our multi-faceted business. The Board and I would like to thank Richard for his contribution, commitment and hard work during a time of significant change at the Group and we wish him well as he embarks on the next stage of his career."

 

Enquiries: 

 

Consort Medical

Tel: +44 (0) 1442 867920

Jonathan Glenn - Chief Executive Officer

Richard Cotton - Chief Financial Officer

FTI Consulting

Tel: +44 (0) 20 3727 1000

Ben Atwell / Simon Conway

 

Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, injectables ocular products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKMGMRFVRGVZM
Date   Source Headline
15th Jun 20123:12 pmRNSDirector/PDMR Shareholding
14th Jun 20127:00 amRNSDirectorate
14th Jun 20127:00 amRNSPreliminary Results
6th Jun 20121:57 pmRNSBlocklisting Interim Review
1st May 201210:21 amRNSTotal Voting Rights
30th Apr 20127:00 amRNSFDA Approval Proprietary Integrated Dose Counter
20th Apr 201210:54 amRNSHolding(s) in Company
16th Apr 201211:37 amRNSBlocklisting Interim Review
28th Mar 20124:36 pmRNSHolding(s) in Company
22nd Mar 20129:58 amRNSAnnual Information Update
20th Mar 20124:25 pmRNSReplacement Interim Management Statement
20th Mar 20121:07 pmRNSInterim Management Statement
1st Mar 20129:00 amRNSTotal Voting Rights
17th Feb 201210:09 amRNSHolding(s) in Company
23rd Jan 20129:45 amRNSBlocklisting Interim Review
13th Dec 20112:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20111:34 pmRNSBlocklisting Interim Review
1st Dec 20117:00 amRNSInterim results for the six months ended 31/10/11
19th Oct 20114:03 pmRNSHolding(s) in Company
17th Oct 20113:13 pmRNSHolding(s) in Company
14th Oct 20119:39 amRNSBlocklisting Interim Review
7th Oct 201112:13 pmRNSHolding(s) in Company
5th Oct 20114:47 pmRNSHolding(s) in Company
4th Oct 20117:00 amRNSSecond Nasal Drug Delivery Contract
27th Sep 20114:33 pmRNSHolding(s) in Company
26th Sep 20113:01 pmRNSHolding(s) in Company
2nd Sep 201110:21 amRNSTotal Voting Rights
1st Sep 20112:50 pmRNSResult of AGM
1st Sep 20112:47 pmRNSDirectorate Change
1st Sep 201112:40 pmRNSInterim Management Statement
1st Sep 20117:00 amRNSNasal Drug Delivery Contract
24th Aug 20114:35 pmRNSHolding(s) in Company
2nd Aug 20111:51 pmRNSDirector/PDMR Shareholding
2nd Aug 20111:47 pmRNSDirector/PDMR Shareholding
28th Jul 20119:14 amRNSAnnual Financial Report
20th Jul 20117:00 amRNSFurther re Investment in Atlas Genetics
30th Jun 20111:58 pmRNSTotal Voting Rights
24th Jun 20119:06 amRNSHolding(s) in Company
21st Jun 201112:33 pmRNSBlocklisting Interim Review
16th Jun 20117:00 amRNSPreliminary results for the year ended 30/04/11
2nd Jun 20117:00 amRNSBlocklisting Interim Review
10th May 20119:27 amRNSHolding(s) in Company
14th Apr 201110:20 amRNSBlocklisting Interim Review
4th Apr 201110:29 amRNSHolding(s) in Company
1st Apr 20111:51 pmRNSHolding(s) in Company
23rd Mar 20112:04 pmRNSAnnual Information Update
14th Mar 20117:00 amRNSInterim Management Statement
15th Feb 20114:14 pmRNSHolding(s) in Company
9th Feb 201111:15 amRNSDirectorate Change
7th Feb 20117:00 amRNSPartners with Atlas Genetics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.